S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
The Strategic Gold Play You Haven't Heard About (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Would Buffett Approve of This Growth Strategy? (Ad)
Low PE Growth Stocks: Unlocking Investment Opportunities
Why Ralph Lauren Should Be On Your Holiday Wishlist
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
3 Reliable Growing Dividends Near Rock-Bottom Prices
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
The Strategic Gold Play You Haven't Heard About (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Would Buffett Approve of This Growth Strategy? (Ad)
Low PE Growth Stocks: Unlocking Investment Opportunities
Why Ralph Lauren Should Be On Your Holiday Wishlist
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
3 Reliable Growing Dividends Near Rock-Bottom Prices
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
The Strategic Gold Play You Haven't Heard About (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Would Buffett Approve of This Growth Strategy? (Ad)
Low PE Growth Stocks: Unlocking Investment Opportunities
Why Ralph Lauren Should Be On Your Holiday Wishlist
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
3 Reliable Growing Dividends Near Rock-Bottom Prices
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
The Strategic Gold Play You Haven't Heard About (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Would Buffett Approve of This Growth Strategy? (Ad)
Low PE Growth Stocks: Unlocking Investment Opportunities
Why Ralph Lauren Should Be On Your Holiday Wishlist
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
3 Reliable Growing Dividends Near Rock-Bottom Prices
NASDAQ:BIVI

BioVie (BIVI) Stock Forecast, Price & News

$3.41
-0.01 (-0.29%)
(As of 10/3/2023 ET)
Compare
Today's Range
$3.21
▼
$3.50
50-Day Range
$2.75
▼
$4.76
52-Week Range
$2.40
▼
$14.38
Volume
179,792 shs
Average Volume
266,989 shs
Market Capitalization
$125.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.50
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

BioVie MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
237.2% Upside
$11.50 Price Target
Short Interest
Bearish
14.92% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$63,926 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.23) to ($1.45) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.71 out of 5 stars

Medical Sector

816th out of 965 stocks

Pharmaceutical Preparations Industry

386th out of 450 stocks

See Top Rated MarketRank™ Stocks Here

BIVI stock logo

About BioVie (NASDAQ:BIVI) Stock

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

BIVI Price History

BIVI Stock News Headlines

September 26, 2023 | proactiveinvestors.com
BioVie to announce topline data from Phase 3 Alzheimer’s Disease trial by year-end
September 26, 2023 | finance.yahoo.com
BioVie Announces Completion of Last Patient Treatment Visit in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer's Disease
October 4, 2023 | Edge On The Street (Ad)
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
September 24, 2023 | americanbankingnews.com
Head-To-Head Review: Elite Pharmaceuticals (OTCMKTS:ELTP) and BioVie (NASDAQ:BIVI)
September 21, 2023 | finance.yahoo.com
BioVie's Lead Drug Candidate Aims To Treat Neurodegenerative Disease By Targeting Inflammation
September 20, 2023 | proactiveinvestors.com
BioVie to participate in Cantor Fitzgerald Global Healthcare...BioVie to participate in Cantor Fitzgerald Global Healthcare...
September 20, 2023 | finanznachrichten.de
BioVie Pharma: BioVie's Lead Drug Candidate Aims To Treat Neurodegenerative Disease By Targeting Inflammation
September 19, 2023 | finance.yahoo.com
BioVie to Participate in the Cantor Fitzgerald Global Healthcare Conference
October 4, 2023 | Edge On The Street (Ad)
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
September 7, 2023 | finance.yahoo.com
BioVie Hosting Virtual KOL Event on NE3107 in Alzheimer’s Disease Today, September 7, 2023
August 31, 2023 | finance.yahoo.com
BioVie to Host Virtual KOL Event on NE3107 in Alzheimer’s Disease on September 7, 2023
August 30, 2023 | finance.yahoo.com
Although BioVie Inc. (NASDAQ:BIVI) insiders have sold lately, they have the highest ownership with 64% stake
August 28, 2023 | uk.news.yahoo.com
Down -29.2% in 4 Weeks, Here's Why You Should You Buy the Dip in BioVie Inc. (BIVI)
August 28, 2023 | proactiveinvestors.com
BioVie showcases promising data for NE3107 at international Parkinson’s Disease event
August 28, 2023 | finance.yahoo.com
BioVie Presents Data for NE3107 at 2023 International Congress of Parkinson’s Disease and Movement Disorders
August 24, 2023 | finance.yahoo.com
Down -23.45% in 4 Weeks, Here's Why You Should You Buy the Dip in BioVie Inc. (BIVI)
August 11, 2023 | finanznachrichten.de
BioVie and Soligenix Interviews to Air on the RedChip Money Report on Bloomberg TV
August 11, 2023 | finance.yahoo.com
BioVie and Soligenix Interviews to Air on the RedChip Money Report(R) on Bloomberg TV
July 20, 2023 | proactiveinvestors.com
BioVie issues letter to shareholders highlights latest update on NE3107 for Alzheimer's Disease
July 18, 2023 | finanznachrichten.de
BioVie, Inc.: BioVie Issues Letter to Shareholders
July 17, 2023 | finance.yahoo.com
BioVie Presents Data Showing How NE3107 May Potentially Regulate DNA Methylation of Specific Genes in a Manner Highly Correlated to Observed Improvements in Cognition and Biomarkers of Disease
July 10, 2023 | finance.yahoo.com
BioVie to Present Data Showing How NE3107 Potentially Regulates DNA Methylation of Specific Genes in a Manner Highly Correlated to Observed Improvements in Cognition and Biomarkers of Disease
June 26, 2023 | technews.tmcnet.com
BioVie Presents Data Highlighting Role of Insulin Resistance and Neuroinflammation in the Development of Mild to Moderate in Alzheimer's Disease
June 26, 2023 | finance.yahoo.com
BioVie Presents Data Highlighting Role of Insulin Resistance and Neuroinflammation in the Development of Mild to Moderate in Alzheimer’s Disease
June 23, 2023 | seekingalpha.com
BioVie to join Russell 2000 and Russell 3000 indexes
June 23, 2023 | proactiveinvestors.com
BioVie set to join Russell 2000 and Russell 3000 indexes
June 22, 2023 | marketwatch.com
BioVie To Present of NE3017 in Alzheimer's Disease Data at 83rd Scientific Sessions of the American Diabetes Association
See More Headlines
Receive BIVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioVie and its competitors with MarketBeat's FREE daily newsletter.

BIVI Company Calendar

Last Earnings
8/16/2023
Today
10/04/2023
Next Earnings (Estimated)
11/03/2023
Fiscal Year End
6/30/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BIVI
CUSIP
N/A
CIK
1580149
Web
bioviepharma.com
Phone
(775) 888-3162
Fax
N/A
Employees
18
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.50
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+237.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.54)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-50,260,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-290.97%
Return on Assets
-133.71%

Debt

Debt-to-Equity Ratio
0.34
Current Ratio
2.35
Quick Ratio
2.35

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.42 per share
Price / Book
8.12

Miscellaneous

Outstanding Shares
36,800,000
Free Float
6,441,000
Market Cap
$125.49 million
Optionable
Not Optionable
Beta
1.67
13 Stocks Institutional Investors Won't Stop Buying Cover
13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Cuong Viet Do M.B.A. (Age 57)
    MBA, Pres, CEO & Director
    Comp: $1.08M
  • Ms. Joanne Wendy Kim CPA (Age 68)
    CFO, Treasurer & Corp. Sec.
    Comp: $397.38k
  • Dr. Joseph M. Palumbo M.D. (Age 63)
    Chief Medical Officer
    Comp: $722k
  • Dr. Penelope Markham Ph.D. (Age 57)
    Exec. VP of Liver Disease R&D
  • Ms. Denise Smith
    Sr. VP of Manufacturing & Devel.
  • Dr. Christopher L. Reading Ph.D. (Age 75)
    Exec. VP of Neuroscience R&D
  • Mr. Clarence N. Ahlem (Age 68)
    Exec. VP of Neuroscience Product Devel.
  • Ms. Sarah Overton Hoit (Age 56)
    Chief Social Impact Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













BIVI Stock - Frequently Asked Questions

Should I buy or sell BioVie stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioVie in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BIVI shares.
View BIVI analyst ratings or view top-rated stocks.

What is BioVie's stock price forecast for 2023?

2 brokers have issued 1-year price objectives for BioVie's stock. Their BIVI share price forecasts range from $11.00 to $12.00. On average, they anticipate the company's share price to reach $11.50 in the next twelve months. This suggests a possible upside of 237.2% from the stock's current price.
View analysts price targets for BIVI or view top-rated stocks among Wall Street analysts.

How have BIVI shares performed in 2023?

BioVie's stock was trading at $7.77 on January 1st, 2023. Since then, BIVI shares have decreased by 56.1% and is now trading at $3.41.
View the best growth stocks for 2023 here.

Are investors shorting BioVie?

BioVie saw a increase in short interest in September. As of September 15th, there was short interest totaling 1,980,000 shares, an increase of 30.3% from the August 31st total of 1,520,000 shares. Based on an average daily volume of 238,600 shares, the short-interest ratio is presently 8.3 days. Currently, 14.9% of the shares of the stock are sold short.
View BioVie's Short Interest.

When is BioVie's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 3rd 2023.
View our BIVI earnings forecast.

How were BioVie's earnings last quarter?

BioVie Inc. (NASDAQ:BIVI) issued its quarterly earnings data on Wednesday, August, 16th. The company reported ($0.23) earnings per share for the quarter, beating analysts' consensus estimates of ($0.37) by $0.14.

What is BioVie's stock symbol?

BioVie trades on the NASDAQ under the ticker symbol "BIVI."

How do I buy shares of BioVie?

Shares of BIVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioVie's stock price today?

One share of BIVI stock can currently be purchased for approximately $3.41.

How much money does BioVie make?

BioVie (NASDAQ:BIVI) has a market capitalization of $125.49 million. The company earns $-50,260,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis.

How can I contact BioVie?

The official website for the company is bioviepharma.com. The company can be reached via phone at (775) 888-3162 or via email at bmackle@lifesciadvisors.com.

This page (NASDAQ:BIVI) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -